Deciphera Pharmaceuticals Inc (DCPH)

Precedente Chiudi:

$25.37

Aprire:

$25.39

Volume 24 ore:

1.83M

Capitalizzazione di mercato:

$2.09B

Reddito:

$163.36M

Utile/perdita netta:

$-194.94M

Rapporto P/E:

-10.80

EPS:

-2.35

Flusso di cassa netto:

$-147.48M

1 W Prestazione:

-0.04%

1M Prestazione:

+62.21%

6M Prestazione:

+124.31%

1 anno Prestazione:

+82.26%

Intervallo 1D:

$25.36

$25.40

Portata 52W:

$9.90

$25.47

Deciphera Pharmaceuticals Inc Stock (DCPH) Company Profile

Nome

Deciphera Pharmaceuticals Inc

Settore

Healthcare (1213)

Industria

Drug Manufacturers - Specialty & Generic (3)

Telefono

781-209-6400

Indirizzo

500 Totten Pond Road, 6th Floor, Waltham, MA

Dipendente

63

Cinguettio

@Deciphera

Prossima data di guadagno

2024-06-03

Ultimi documenti SEC

DCPH's Discussions on Twitter

Deciphera Pharmaceuticals Inc Stock (DCPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-30	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-08-10	Aggiornamento	Stifel	Hold → Buy
2023-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2022-08-29	Iniziato	Cowen	Outperform
2022-08-05	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2022-02-28	Downgrade	Barclays	Equal Weight → Underweight
2021-11-08	Downgrade	Barclays	Overweight → Equal Weight
2021-11-08	Downgrade	Canaccord Genuity	Buy → Hold
2021-11-08	Downgrade	Stifel	Buy → Hold
2021-11-05	Downgrade	Truist	Buy → Hold
2021-09-30	Ripresa	Stifel	Buy
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-02-10	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-12-03	Iniziato	Stifel	Buy
2020-09-14	Ripresa	JP Morgan	Neutral
2020-05-07	Downgrade	Nomura	Buy → Neutral
2020-03-04	Iniziato	Barclays	Overweight
2019-12-20	Reiterato	Jefferies	Buy
2019-10-29	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2019-10-22	Iniziato	JMP Securities	Mkt Outperform
2019-10-03	Iniziato	H.C. Wainwright	Buy
2019-09-30	Iniziato	Jefferies	Buy
2019-07-18	Iniziato	Deutsche Bank	Buy
2018-12-31	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-09-25	Iniziato	Leerink Partners	Underperform
2018-08-29	Iniziato	Raymond James	Outperform
2018-07-05	Iniziato	SunTrust	Buy
2018-06-19	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-02-16	Iniziato	B. Riley FBR, Inc.	Buy
2017-10-23	Iniziato	JMP Securities	Mkt Outperform
2017-10-23	Iniziato	JP Morgan	Overweight
2017-10-23	Iniziato	Nomura	Buy
2017-10-23	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Deciphera Pharmaceuticals Inc Borsa (DCPH) Ultime notizie

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Wall Street Breakfast: The Week Ahead

Seeking Alpha

The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine

Zacks Investment Research

Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More

Zacks Investment Research

Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Benzinga

US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?

Benzinga

Deciphera Pharmaceuticals Inc Azioni (DCPH) Dati Finanziari

Deciphera Pharmaceuticals Inc (DCPH) Reddito 2024

Deciphera Pharmaceuticals Inc (DCPH) Reddito netto 2024

Deciphera Pharmaceuticals Inc (DCPH) Flusso di cassa 2024

Deciphera Pharmaceuticals Inc (DCPH) Utile per azione 2024